Naproxen etemesil

Drug Profile

Naproxen etemesil

Alternative Names: LT-NS001; MX-1094

Latest Information Update: 19 Jun 2015

Price : $50

At a glance

  • Originator Medinox
  • Developer Logical Therapeutics
  • Class Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 26 May 2010 Naproxen etemesil is available for licensing worldwide (http://www.logicaltx.com)
  • 26 Apr 2010 Phase-II clinical trials in Osteoarthritis in United Kingdom (PO)
  • 26 Apr 2010 Phase-II clinical trials in Osteoarthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top